TumorNext-Lynch
When you need to rule out or confirm Lynch syndrome or to determine if your patient can start PD-LI or PD-1 immunotherapy you need a test that gives you the most comprehensive and accurate information. TumorNext-Lynch is a single test that looks at both tumor and germline mutations, giving you clearer information to better guide treatment decisions.
Quick Reference
| Test Code | 8980 |
| Turnaround Time (TAT) | 3-4 weeks |
| Number of Genes | 8 |
- AmbryPort Login or create an account
- Order a Sample Kit
We offer family variant testing at no additional cost
for all blood relatives of patients who undergo full single gene sequencing or multigene panel testing* at Ambry Genetics and are found to have a pathogenic or likely pathogenic variant. No-cost testing of blood relatives must be completed within 90 days of the original Ambry report date.
Order Now*excludes Secondary Findings and SNP Array tests
Why Is This Important?
- Get more complete information to guide healthcare decisions with one test to rule out or confirm Lynch syndrome
- Know if your patient is at an increased risk for other cancers, so you can modify screening and prevention recommendations
- Guide treatment decisions based on BRAF/KRAS/NRAS mutation status
- Guide treatment options for PD-L1/PD-1 immunotherapy based on MMR deficiency status
When To Consider Testing
- Patients with colorectal or endometrial cancer who are suspicious for Lynch syndrome due to abnormal MSI/IHC
- Patients with abnormal MSI and/or IHC results, with no germline Lynch syndrome gene mutations found
Test Description
- Tumor and germline paired analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM
- Microsatellite instability (MSI)
- MLH1 promoter hypermethylation analysis.
- Option to add on BRAF (V600E), NRAS, and KRAS targeted analysis
- The following tumor types will be accepted (assuming all other specimen requirements are met): colorectal, endometrial, ovarian, Fallopian tube, primary peritoneal, small bowel, stomach, pancreas, appendiceal, gallbladder, bladder, ureter, renal pelvis, sebaceous cancer, prostate, and colorectal polyps with high grade dysplasia. For more details, please refer to the Tumor Specimen Requirements.
